Clariane SE (CHIX:CLARIP) 10-Year RORE % : -72.23% (As of Dec. 2025)


CHIX:CLARIP Clariane SE CHIX:CLARIP
63 GF Score
Price €4.13
GF Value €2.47
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Clariane SE 10-Year RORE %?

Clariane SE CHIX:CLARIP 63 10-Year RORE % is -72.23 as of Dec. 2025. GuruFocus rates CHIX:CLARIP with a GF Score™ of 63/100 and a GF Value™ of €2.47 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 322 Healthcare Providers & Services companies, Clariane SE ranks worse than 95.03% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Clariane SE's 10-Year RORE % for the quarter that ended in Dec. 2025 was -72.23%.

The industry rank for Clariane SE's 10-Year RORE % or its related term are showing as below:

CHIX:CLARIp's 10-Year RORE % is ranked worse than
95.03% of 322 companies
in the Healthcare Providers & Services industry
Industry Median: 6.25 vs CHIX:CLARIp: -72.23

Clariane SE  (CHIX:CLARIp) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Clariane SE 10-Year RORE % Related Terms


Clariane SE 10-Year RORE % Historical Data

* Premium members only.

The historical data trend for Clariane SE's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clariane SE 10-Year RORE % Chart

Clariane SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.41 -9.15 -55.12 -67.42 -72.23

Clariane SE Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.12 -106.21 -67.42 -40.57 -72.23

CHIX:CLARIP vs HCA, THC, DVA: 10-Year RORE % Comparison

For the Medical Care Facilities subindustry, Clariane SE's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clariane SE 10-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Clariane SE's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Clariane SE's 10-Year RORE % falls into.


CHIX:CLARIP
63GF Score
Clariane SE CHIX:CLARIP
10-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clariane SE 10-Year RORE % Calculation

Clariane SE's 10-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( 0.004-0.904 )/( 3.062-1.816 )
=-0.9/1.246
=-72.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 10-year before.

Frequently Asked Questions Learn more about 10-Year RORE % →
What does a 10-Year RORE % of -72.23 mean?
Clariane SE (CHIX:CLARIP) has a 10-Year RORE % of -72.23 as of Dec. 2025. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Clariane SE and its competitors. According to the industry distribution chart, Clariane SE ranks #306 out of 322 companies in the Healthcare Providers & Services industry, placing it in the top 95%.
Is Clariane SE's 10-Year RORE % too high?
Clariane SE's current 10-Year RORE % is -72.23. Based on the distribution chart, Clariane SE ranks #306 out of 322 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Clariane SE has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's 10-Year RORE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Clariane SE ranks #306 out of 322 companies for 10-Year RORE %. This places Clariane SE in the lower half of its industry. The industry median 10-Year RORE % is 6.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Healthcare Providers & Services company?
The median 10-Year RORE % among Healthcare Providers & Services companies is 6.25, based on 322 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Clariane SE and its competitors. For the Healthcare Providers & Services industry, the median 10-Year RORE % is 6.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clariane SE's current 10-Year RORE % is -72.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (CHIX:CLARIP) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.47, compared to a current price of €4.13 — trading 67% above its estimated fair value. The current 10-Year RORE % is -72.23. Clariane SE's overall GF Score™ is 63/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Clariane SE (CHIX:CLARIP), the current 10-Year RORE % is -72.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clariane SE (CHIX:CLARIP) Overvalued in 2026?

Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued. The current stock price of €4.13 is trading 67% above its estimated GF Value™ of €2.47. GuruFocus considers Clariane SE to be Significantly Overvalued.

Key valuation signals for CHIX:CLARIP:

  • 10-Year RORE %: -72.23
  • GF Value™: €2.47 vs. price of €4.13 (67% above fair value)
  • GF Score™: 63/100 with 9 warning signs

No single metric tells the full story. See the CHIX:CLARIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clariane SE Business Description

Address 21-25, Rue Balzac, Paris, FRA, 75008
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
63GF Score

Get the complete analysis for CHIX:CLARIP

10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.13
Price
€2.47
GF Value